The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
Open accessAbstract
Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of ceftriaxone and/or cefuroxime axetil in the management of community-acquired pneumonia in adults. Patients received either intravenous and/or oral levofloxacin (500 mg once daily) or the comparative agents, parenteral ceftriaxone (1 to 2 g once to twice daily) and/or oral cefuroxime axetil (500 mg twice daily). Erythromycin or doxycycline could be added to the comparator arm at the investigator's discretion. The decision to use an intravenous or oral antimicrobial agent for initial therapy was made by the investigator. Clinical and microbiological evaluations were completed at the baseline, during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Four hundred fifty-six patients (226 given levofloxacin and 230 administered ceftriaxone and/or cefuroxime axetil) were evaluable for clinical efficacy. Streptococcus pneumoniae and Haemophilus influenzae were isolated in 15 and 12%, respectively, of clinically evaluable patients. One hundred fifty atypical pathogens were identified: 101 were Chlamydia pneumoniae, 41 were Mycoplasma pneumoniae, and 8 were Legionella pneumophila. Clinical success at 5 to 7 days posttherapy was superior for the levofloxacin group (96%) compared with the ceftriaxone and/or cefuroxime axetil group (90%) (95% confidence interval [CI] of -10.7 to -1.3). Among patients with typical respiratory pathogens who were evaluable for microbiological efficacy, the overall bacteriologic eradication rates were superior for levofloxacin (98%) compared with the ceftriaxone and/or cefuroxime axetil group (85%) (95% CI of -21.6 to -4.8). Levofloxacin eradicated 100% of the most frequently reported respiratory pathogens (i.e., H. influenzae and S. pneumoniae) and provided a >98% clinical success rate in patients with atypical pathogens. Both levofloxacin and ceftriaxone-cefuroxime axetil eradicated 100% of the S. pneumoniae cells detected in blood culture. Drug-related adverse events were reported in 5.8% of patients receiving levofloxacin and in 8.5% of patients administered ceftriaxone and/or cefuroxime axetil. Gastrointestinal and central and peripheral nervous system adverse events were the most common events reported in each treatment group. In conclusion, these results demonstrate that treatment with levofloxacin is superior to ceftriaxone and/or cefuroxime axetil therapy in the management of community-acquired pneumonia in adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Bartlett, J. G., & Mundy, L. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332408 · Cited by 982
Fang, G.-D., Fine, M., Orloff, J., Arisumi, D., Yu, V. L., Kapoor, W., Grayston, J. T., Wang, S. P., Kohler, R., Muder, R. R., et al. (1990) · Medicine · doi:10.1097/00005792-199009000-00004 · Cited by 895
Self-citationKuo, C. C., Jackson, L. A., Campbell, L. A., & Grayston, J. T. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.451 · Cited by 819
Cefuroxime: A Review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use
Brogden, R. N., Heel, R. C., Speight, T. M., & Avery, G. S. (1979) · Drugs · doi:10.2165/00003495-197917040-00001 · Cited by 311
Pneumonia Associated with the TWAR Strain of Chlamydia
MARRIE, T. J., GRAYSTON, J. T., WANG, S.-P., & KUO, C.-C. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-507 · Cited by 240
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
Chien, S. C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J., Williams, R. R., Fowler, C. L., Cheung, W. K., & Chow, A. T. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2256 · Cited by 217
Self-citationPaladino, J. A., Sperry, H. E., Backes, J. M., Gelber, J. A., Serrianne, D. J., Cumbo, T. J., & Schentag, J. J. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90181-v · Cited by 163
Grayston, J. T., Diwan, V. K., Cooney, M., & Wang, S. P. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.1.169 · Cited by 128
Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy
Lee, B. L., Padula, A. M., Kimbrough, R. C., Jones, S. R., Chaisson, R. E., Mills, J., & Sande, M. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250719 · Cited by 112
Cited by
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Musher, D. M., & Fine, M. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313954 · Cited by 2,286
Self-citationNiederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.7.at1010 · Cited by 2,150
Self-citationBTS guidelines for the management of community acquired pneumonia in adults: update 2009
Lim, W. S., Baudouin, S. V., George, R. C., Hill, A. T., Jamieson, C., Le Jeune, I., Macfarlane, J. T., Read, R. C., Roberts, H. J., Levy, M. L., et al. (2009) · Thorax · doi:10.1136/thx.2009.121434 · Cited by 1,420
Mycoplasma pneumoniae and Its Role as a Human Pathogen
Waites, K. B., & Talkington, D. F. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.697-728.2004 · Cited by 1,339
Mandell, L. A., Bartlett, J. G., Dowell, S. F., File, T. M., Musher, D. M., & Whitney, C. (2003) · Clinical Infectious Diseases · doi:10.1086/380488 · Cited by 1,004
Self-citationGuidelines for the management of adult lower respiratory tract infections
Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., & Verheij, T. J. M. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00055705 · Cited by 895
Association of adverse events with antibiotic use in hospitalized patients.
Tamma, P. D., Avdic, E., Li, D. X., Dzintars, K., & Cosgrove, S. E. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1938 · Cited by 800
A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia
Marrie, T. J. (2000) · JAMA · doi:10.1001/jama.283.6.749 · Cited by 731
Mandell, L. A., Marrie, T. J., Grossman, R. F., Chow, A. W., Hyland, R. H., & and the Canadian Community-Acquired Pneumonia Working Group (2000) · Clinical Infectious Diseases · doi:10.1086/313959 · Cited by 664
Heffelfinger, J. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1399 · Cited by 610
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
Mechanisms of fluoroquinolone resistance
Hooper, D. C. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0068 · Cited by 488
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
Epidemiology and clinical management of Legionnaires' disease
Phin, N., Parry-Ford, F., Harrison, T., Stagg, H. R., Zhang, N., Kumar, K., Lortholary, O., Zumla, A., & Abubakar, I. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70713-3 · Cited by 438
A Critical Review of the Fluoroquinolones: Focus on Respiratory Infections
Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., Smith, H., & Hoban, D. J. (2002) · Drugs · doi:10.2165/00003495-200262010-00002 · Cited by 344
High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment Paradigm
Dunbar, L. M., Wunderink, R. G., Habib, M. P., Smith, L. G., Tennenberg, A. M., Khashab, M. M., Wiesinger, B. A., Xiang, J. X., Zadeikis, N., & Kahn, J. B. (2003) · Clinical Infectious Diseases · doi:10.1086/377539 · Cited by 335
Self-citationMacfarlane, J. (2001) · Thorax · doi:10.1136/thorax.56.2.109 · Cited by 333
Fluoroquinolone resistance among Gram-positive cocci
Hooper, D. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00369-9 · Cited by 320
Ball, P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.31 · Cited by 290
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
(2001) · PubMed · doi:10.1136/thorax.56.suppl_4.iv1 · Cited by 272
Mizunaga, S., Kamiyama, T., Fukuda, Y., Takahata, M., & Mitsuyama, J. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki163 · Cited by 78
Metadata
- Authors
- File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R., Kojak, C., & Rubin, A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-09
- Volume
- 41
- Issue
- 9
- Pages
- 1965-1972
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1843993979
- Cited by
- 360
- References
- 12
- FWCI
- 27.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.